Durvalumab联合放疗用于不可手术局部晚期NSCLC不适合同步放化疗患者
2年无进展生存率达39%,达到主要终点,2年总生存率为54%,3/4级治疗相关不良事件发生率为21%。
要点
- 不适合同步放化疗的局部晚期NSCLC患者,放疗联合Durvalumab的2年PFS为39%,优于历史对照的20%。
- 2年OS为54%,体能状态较好和PD-L1阳性与更好的PFS相关。
- 3/4级治疗相关不良事件发生率21%,5级不良事件7%(放射性肺炎2例、心脏骤停2例)。
核心结论
- 胸部放疗联合同步及巩固Durvalumab对不适合同步放化疗的局部晚期NSCLC患者是 promising 的治疗选择,PFS优于历史对照且安全性可接受。
研究设计与样本
- 患者接受常规分割放疗联合同步及巩固Durvalumab(固定剂量1500 mg,每4周一次),最长12个月。
- 主要终点为2年无进展生存率,预设目标为36%,历史对照为20%(把握度86%)。
主要发现
- 2年无进展生存率为39%(单侧CI 29至100),达到主要终点。
- 2年总生存率为54%。
- 体能状态较好和PD-L1阳性与改善的PFS相关;体能状态较好与改善的OS相关;PD-L1阳性与更好的癌症特异性生存相关。
- 3/4级治疗相关不良事件发生于12例(21%)患者。
- 5级不良事件发生于4例(7%)患者,包括放射性肺炎2例和心脏骤停2例;18例(31%)患者因不良事件提前停用Durvalumab。
关键数值与推荐
- 纳入患者中位年龄82岁(IQR 76-86);PD-L1阴性16例(28%);ECOG评分2分8例(14%),1分46例(79%),0分4例(7%)。
- 主要终点2年PFS预设为36%对比历史20%,实际达到39%(单侧CI 29至100)。
临床怎么用
- 对于因年龄、合并症或虚弱不适合同步放化疗的局部晚期NSCLC患者,可考虑放疗联合同步及巩固Durvalumab作为治疗选择。
- 治疗期间需密切监测放射性肺炎和心脏不良事件,本研究中5级不良事件包括放射性肺炎和心脏骤停。
局限性
- 历史对照比较可能存在混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Concurrent platinum-based chemotherapy and radiation therapy (cCRT) followed by consolidative durvalumab is the standard of care (SoC) for fit patients with inoperable, locally advanced non-small cell lung cancer (LA-NSCLC). However, no SoC exists for patients who are cCRT-ineligible because of age, comorbidities, or frailty. Here, we investigated the efficacy and adverse events (AEs) of concurrent and consolidative durvalumab with definitive radiation therapy (RT) without chemotherapy. METHODS: In this multicenter, single-arm, prospective phase II study, patients received conventionally fractionated RT plus concurrent and consolidative durvalumab (1,500 mg fixed dose once every 4 weeks) for up to 12 months. The primary end point was 2-year progression-free survival (PFS) of 36% compared with historical results of 20% with sequential CRT (86% power). Additional end points included overall survival (OS) and cancer-specific survival (CSS). RESULTS: Fifty-eight patients (median age 82 years [IQR, 76-86]; 16 [28%] PD-L1-negative; eight [14%] Eastern Cooperative Oncology Group [ECOG] score 2; 46 [79%] ECOG score 1; four [7%] ECOG score 0) were treated per protocol. The study met its primary end point with a 2-year PFS of 39% (one-sided CI, 29 to 100) and a 2-year OS of 54%. Better performance status and PD-L1 positivity were associated with improved PFS; better ECOG was associated with improved OS; PD-L1 positivity was associated with better CSS. Grade 3/4 treatment-related AEs occurred in 12 (21%) patients. Grade 5 AEs occurred in four (7%) patients (radiation pneumonitis (n = 2) and cardiac arrest (n = 2)). Durvalumab was discontinued early because of AEs in 18 (31%) patients. CONCLUSION: Thoracic RT with concurrent and consolidative durvalumab is a promising treatment option for cCRT-ineligible patients with LA-NSCLC, demonstrating better PFS with a favorable safety profile compared with historical controls.
引用
- Rimner A, Lebow ES, Fitzgerald KJ, et al. Durvalumab With Radiation Therapy in Patients With Inoperable Locally Advanced Non-Small Cell Lung Cancer Ineligible for Concurrent Chemoradiotherapy (DART). J Clin Oncol. 2026. PMID: 42462186. doi:10.1200/JCO-25-02517
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。